<DOC>
	<DOCNO>NCT01218516</DOCNO>
	<brief_summary>The primary objective study compare effect farletuzumab versus placebo combination either platinum agent ( carboplatin ) paclitaxel platinum agent ( carboplatin cisplatin ) pemetrexed follow farletuzumab placebo investigator-assessed progression free survival ( PFS ) determine Response Evaluation Criteria Solid Tumors ( RECIST ) v.1.1 definitive clinical disease progression ( eg , new occurrence positive fluid cytology ) chemotherapynaive participant folate receptoralpha ( FRA ) -expressing Stage IV adenocarcinoma lung .</brief_summary>
	<brief_title>A Safety Efficacy Study Farletuzumab Subjects With Adenocarcinoma Lung</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma lung classify stage IV Confirmed folate receptoralpha ( FRA ) expression IHC Measurable disease least one unidimensionally measurable lesion accord RECIST criterion version 1.1 CT MRI scan ( CT MRI scan must perform within 30 day prior first dose farletuzumab placebo ) Must receive prior chemotherapy , radiation therapy surgery curative intent adenocarcinoma lung Subjects previous chemotherapy adenocarcinoma lung Prior surgery curative intent adenocarcinoma lung Prior radiotherapy adenocarcinoma lung . ( Prior treatment local radiotherapy symptom control [ i.e. , palliative radiation noncurative intent ] permit )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>